Last updated: 2026-09-06 03:39:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Dermata Therapeutics, Inc. (DRMA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.23, with a market capitalization of $6.34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.95 to $6.22. This page covers its latest market performance, valuation, price trends and company information.
$6.34M | |
$1.23 | |
$16,680.00 | |
$0.95 | |
$1.23 | |
37.09K | |
-- | |
-- | |
$6.22 | |
$0.95 | |
-- | |
-- |
Dermata Therapeutics, Inc. (DRMA) last closed at $1.23 as of 2026-09-04 23:24:00, unchanged from the previous close of $1.23.
During the latest regular trading session, DRMA traded between $0.95 and $16,680.00, with a volume of 37.09K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Dermata Therapeutics, Inc. (DRMA) moved from $1.30 to $1.23, representing a decline of 5.77% ($0.07).
The stock traded between $1.20 and $1.26 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 67.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.2%
DRMA is currently trading at $1.23, placing it 5.2% of the way from its 52-week low of $0.95 to its 52-week high of $6.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Dermata Therapeutics, Inc. (DRMA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.